235 related articles for article (PubMed ID: 33123978)
1. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M; Egyed M; Gercheva L; Warzocha K; Kvasnicka HM; Achenbach H; Wu J
Cardiovasc Toxicol; 2021 Mar; 21(3):236-247. PubMed ID: 33123978
[TBL] [Abstract][Full Text] [Related]
2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide: a review of its use in the management of essential thrombocythaemia.
Wagstaff AJ; Keating GM
Drugs; 2006; 66(1):111-31. PubMed ID: 16398570
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
[TBL] [Abstract][Full Text] [Related]
7. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Petrides PE
Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
13. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
[TBL] [Abstract][Full Text] [Related]
14. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
15. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.
Besses C; Zeller W; Alvarez-Larrán A; Coll R; Troy S; Purkayastha J; Martin P; Freitag C
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):787-96. PubMed ID: 22943924
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
20. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]